US biotechnology company Moderna announced on Tuesday that the COVID-19 vaccine was “highly effective” for adolescents between the ages of 12 and 17, according to the results of a full clinical trial.
Also read: Young men avoid vaccination
Moderna says it plans to apply for a permit to use its vaccine for this age group “in early June” with “regulators around the world.”
Another vaccine, the Pfizer / BioNTech vaccine, is already approved for teens in many countries, including the United States.
“We are encouraged that (the vaccine) has proven highly effective in preventing COVID-19 in adolescents,” Stephane Bancel, president of Moderna, said in a statement. “We will submit these results to the FDA and to regulators around the world in early June and apply for permission.”
Moderna’s study involved more than 3,700 participants between the ages of 12 and 17 in the United States, two-thirds of whom received the vaccine, and one-third of them received a placebo.
Moderna said: “After two doses, no case of Covid-19 was observed in the vaccinated group (…) compared to 4 cases in the placebo group, which resulted in the vaccine being 100% effective 14 days after the second dose.” In his statement.
After a dose, an efficacy of 93% was observed, the company specifies.
She said the vaccine is “generally well tolerated” and “no safety concerns have yet been identified.” The side effects observed were the same in adults (pain at the injection site, fatigue, chills, etc.).